{
  "Clinical Information": [],
  "Patent Information": [],
  "Sequence Information": {
    "ID": "AP02875",
    "Peptide Name": "SAAP-148 (synthetic AMPs20; UCLL1; BBMm)",
    "Source": "engineered based on LL-37",
    "Family": "Not found",
    "Gene": "Not found",
    "Sequence": "LKRVWKRVFKLLKRYWRQLKKPVR",
    "Sequence Length": 24,
    "UniProt Entry": "Ref",
    "Protein Existence": "Not found",
    "Biological Activity": [
      "Anti-Gram+",
      "Gram-",
      "Anti-MRSA",
      "Synergistic AMPs",
      "Antibiofilm"
    ],
    "Target Organism": "Not found",
    "Hemolytic Activity": "Not found",
    "Cytotoxicity": "Not found",
    "Binding Target": "Not found",
    "Linear/Cyclic": "Not found",
    "N-terminal Modification": "Not found",
    "C-terminal Modification": "Not found",
    "Nonterminal Modifications and Unusual Amino Acids": "Not found",
    "Stereochemistry": "Not found",
    "Structure": "Unknown",
    "Structure Description": "Not found",
    "Helical Wheel Diagram": "Not found",
    "PDB ID": "",
    "Predicted Structure": "Not found",
    "Formula": "Not found",
    "Absent Amino Acids": "Not found",
    "Common Amino Acids": "Not found",
    "Mass": "Not found",
    "PI": "Not found",
    "Basic Residues": "Not found",
    "Acidic Residues": "Not found",
    "Hydrophobic Residues": "Not found",
    "Net charge": 11,
    "Boman Index": 3.08,
    "Hydrophobicity": "Not found",
    "Aliphatic Index": "Not found",
    "Half Life": "Not found",
    "Extinction Coefficient Cystines": "Not found",
    "Absorbance 280nm": "Not found",
    "Polar Residues": "Not found",
    "Function": "Not found",
    "Hydrophobic residue%": "41%",
    "Crucial residues": ""
  },
  "Literature Information": {
    "Literature": "Sequence analysis: APD analysis reveals that the sequence of this peptide shows 40% similarity toduck cathelicidin dCATH. 20% Arg and 25% Lys, 16% Leu, and 12% Val. Mol. Wt: 3226.041; Mol Formula: C155H260N48O27; Mol ex. coeff.: 12590; GRAVY: -0.979.Activity: SAAP-148 shows broad activity against the ESKAPE pathogens in 50% plasma, including E. faecium LUH15122 (LC99.9 6.4 uM), S. aureus LUH14616 (3.2-12.8), K. pneumoniae LUH15104 (12.8-25.6 uM), A. baumannii RUH875 (1.6-3.2 uM), P. aeruginosa LUH15103 (12.8-25.6 uM), E. cloacae LUH15114 (3.2-12.8 uM), and E. coli LUH15117 (6.4 uM).  Fast killing.MOA:bacteria:A. baumannii: MOA:bacteria:S. aureus: permeated bacterial membranes.Resistance development:no:bacteria:S. aureus:  It did not develop resistance after 20 passages, while rifampicin MIC increased >4096 fold in 15 passages. Resistance development:no:bacteria:A. baumannii: this bacterium didn't develop resistance after 20 passages in the presence of SAAP-148.  Also, resistance development:no:bacteria:E. coli.Synergy:antibiotics:   It also showed synergy with antibiotics teicoplanin against S. aureus biofilms (Koppen et al. 2018).Updated 7/2021; 12/2024",
    "Author": "de Breij A, Riool M, Cordfunke RA, Malanovic N, de Boer L, Koning RI, Ravensbergen E, Franken M, van der Heijde T, Boekema BK, Kwakman PHS, Kamp N, El Ghalbzouri A, Lohner K, Zaat SAJ, Drijfhout JW, Nibbering PH.",
    "Reference": "Sci Transl Med. 2018 Jan 10;10(423). pii: eaan4044. doi: 10.1126/scitranslmed.aan4044.PubMed",
    "Title": "The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms"
  },
  "3D Structure": []
}